stocks logo

DNTH Valuation

Dianthus Therapeutics Inc
$
19.110
-0.160(-0.830%)
  • Overview
  • Forecast
  • Valuation

DNTH Relative Valuation

DNTH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DNTH is overvalued; if below, it's undervalued.

Historical Valuation

No Data

Competitors Valuation Multiple

The average P/S ratio for DNTH's competitors is 44.37, providing a benchmark for relative valuation. Dianthus Therapeutics Inc Corp (DNTH) exhibits a P/S ratio of 194.52, which is 338.45% above the industry average. Given its robust revenue growth of 33.07%, this premium appears sustainable.

FAQ

arrow icon

Is Dianthus Therapeutics Inc (DNTH) currently overvalued or undervalued?

Dianthus Therapeutics Inc (DNTH) is now in the Fair zone, suggesting that its current forward PS ratio of 194.52 is considered Fairly compared with the five-year average of 268.61. The fair price of Dianthus Therapeutics Inc (DNTH) is between 9.57 to 34.98 according to relative valuation methord.
arrow icon

What is Dianthus Therapeutics Inc (DNTH) fair value?

arrow icon

How does DNTH's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Dianthus Therapeutics Inc (DNTH) as of May 20 2025?

arrow icon

What is the current FCF Yield for Dianthus Therapeutics Inc (DNTH) as of May 20 2025?

arrow icon

What is the current Forward P/E ratio for Dianthus Therapeutics Inc (DNTH) as of May 20 2025?

arrow icon

What is the current Forward P/S ratio for Dianthus Therapeutics Inc (DNTH) as of May 20 2025?